Royce Waltrip has over 20 years of experience in clinical development and medical affairs in the pharmaceutical industry. He has led teams in developing drugs to treat schizophrenia, depression, rheumatoid arthritis, pulmonary diseases, and gout. Notable achievements include leading the successful development of Krystexxa for treatment-resistant gout and establishing investigator-initiated trial programs. He also has extensive experience as a psychiatrist, including training and research roles at prestigious universities. Currently, he provides medical monitoring and consultation for clinical trials through ICON Clinical Research.

1. ROYCE W. WALTRIP II, M.D.
98 Linda Lee Circle 609-731-9957
Pittsboro, NC 27312 rwaltripii@ zazenpractice.com
CAREER SUMMARY
Pharmaceutical leader in clinical development and medical affairs with experience in Phases 1 through 4
of clinical development, commercialization and medical affairs across therapeutic areas [CNS (psychiatry
& neurology), Rheumatology, Immunology, Pulmonary]. These activities included FDA interactions and
document preparations, line extension and commercialization of pharmaceutical products, medical
monitoring, safety assessment, pharmacokinetic evaluation, KOL relations, training sales and MSL teams,
managing a scientific grant program, and business development activities. Expert at leading
interdisciplinary teams in a matrix environment. Frequently provided scientific representation of the
company in organizations and meetings. Medical lead on successful development of Krystexxa, approved
in 2010. Extensive fellowship training in schizophrenia and neuroimmunovirology with expertise in
clinical and pre-clinical research methodology.
Experienced leader in clinical care of major mental disorders, teaching and research. Trained at Yale
University Department of Psychiatry (West Haven VAMC, Yale New Haven Hospital and the Yale
Psychiatric Institute). Board certified in psychiatry. Extensive academic and patient care background at
the Maryland Psychiatric Research Center, Johns Hopkins University, and the University of Mississippi
Medical Center. Served as an independent researcher, medical student and resident supervisor, course
leader, and departmental representative on major university committees. Examiner, American Board of
Psychiatry and Neurology, Inc.
PROFESSIONAL INTERESTS:
 PharmaceuticalClinical Development (Phases 1-3), Medical Affairs, Safety Assessment, and
Marketing
 Schizophrenia and Major Psychotic Disorders (Fellowship and faculty of Maryland Psychiatric
Research Center)
 Depression and Medical Implications of Depression
 Neurodegeneration (Alzheimer’s Disease,Dementia of Schizophrenia, Parkinson’s Disease,
MS)
 Neuroimmunology/Virology and Neuropsychiatric Disease (Trained at Johns Hopkins
University)
 Emerging Infectious Diseases
 Microbiome
 Rheumatology, Pulmonary, and Immunopathological Diseases
 Biomarker Development/Translational medicine
 Bioethics/Medical Ethics
 Gout
 Post marketing studies (Phases 3b,4, and Investigator Sponsored Trials)
 Attention Deficit Hyperactivity Disorder
 Pain
PROFESSIONAL EXPERIENCE
ICON Clinical Research, North Wales, PA. 9/2012 – 9/2015
Director, Medical Affairs Neuroscience (Clinical Development,Business Development)
 Global and Regional Medical Monitor
 Responsibilities
 Provide medical consultation on studies including: Serious Adverse Event reporting to sponsors
and regulatory authorities, oversee and communicate safety issues to Vice President, Medical and
Regulatory Affairs and sponsors, central lab report review and CRF safety review. Also, review
and approve: protocols for clients and investigators, exception approvals, inclusion/exclusion
criteria, case report forms, listings/coding, Serious Adverse Event narratives, informed consent
forms (when applicable), follow-up of Serious Adverse Events, and miscellaneous

2. P a g e | 2
documentation. Participation in investigator meeting presentations, acting as information resource
to investigators, rotating on-call schedule for safety monitoring after hours, training project teams
in therapeutic areas on an on-going basis, as well as, providing medical support to ICON staff,
and assist in marketing when appropriate.
 Managerial Responsibility for overall program profitability and Matrix Management of team
Drug Safety Monitors, Drug Safety Associates, Physician Regional Medical Monitors, and
Physician Medical Monitors in training.
 Projects
 Schizophrenia Phase 1 Injectable Antipsychotic Microspheres
 Schizophrenia Phase 3 Treatment for Comorbid Alcohol Use Disorder
 Major Depressive Disorder Adjunct Treatment in Partial Responders
 Huntington’s Disease Imaging
 Treatment of Transfusional Iron Overload
 Team Support in Rheumatoid Arthritis
 Trained internal ICON team in disease area and sponsor drugs and mechanisms of action.
 Business Development
 Assess projects submitted for Requests for Proposal for scientific coherence, study design, and
feasibility.
 Determine necessary site characteristics.
 Develop a country and site distribution plan in collaboration with ICON Feasibility.
 Develop a budget for medical activities.
 Develop a proposal strategy
 Write proposal, develop slides, and participate in bid defense meetings.
TALECRIS BIOTHERAPEUTICS, RTP, NC 2/2010-6/2011
Plasma Products and Biotherapeutics Company
Senior Medical Director and Group Lead for Immunology, Pulmonology, and Oncology Clinical
Development (Blended Clinical Development and Medical Affairs)
 Led multidisciplinary Phase 4 project teams and provided medical monitoring for studies in
immunology and pulmonology.
 Safety evaluation to address FDA concern regarding class effect (white paper).
 Served as Medical and scientific lead for commercialization activities in immunology with Gamunex
(IVIG) and pulmonary with Prolastin (alpha 1 antitrypsin) and managed multi-disciplinary scientific
and strategic analysis of new indications (Grave’s ophthalmopathy, myasthenia gravis, ventilator-
associated pneumonia, inflammatory GI disease, cystic fibrosis, COPD).
 Establish relationship with relevant scientific community in each indication
 Create Clinical Development Plans
 Protocol development (Design FDA approval program, obtain KOL expert advisor input, write
protocol)
 Matrix management of multidisciplinary team for opportunity valuation
 Managed and led multiple scientific advisory boards.
 Participated in FDA meetings (efficacy study protocol approval, Population PK design, sampling
issues).
 Worked on development of oral immunoglobulin for microbiome-related GI disease.
 Interim Group Lead for Thromolytic Development
 Managed Thrombolytic Development interdisciplinary team and provided medical and scientific
direction.
 Recruited and participated in hiring the permanent lead.
 Led the development team through DSMB program review.
 Performed business development in-license assessments.
 Served as a Publication Committee member.
ARDEA BIOSCIENCES, San Diego, CA 1/2010

3. P a g e | 3
Biotechnology company focused on the development of small-molecule therapeuticsfor the treatment of
serious diseases.
Consultant/Senior Director
 Provided gout expertise and served as the liaison with expert contacts in the gout field for the
development of RDEA 594, an oral URAT 1 transporter inhibitor.
 Created clinical development plan documents
SAVIENT PHARMACEUTICALS, INC., East Brunswick, NJ 1/2005-9/2009
Specialty Pharmaceutical Company
Senior Director Clinical Development and Medical Affairs
 Served as project physician for the development of prosaptide in pain (HIV neuropathy).
 Served as project physician for the development of Krystexxa, an infusional pegylated uricase for the
treatment of severe treatment resistant gout. Responsible for medical aspects of study conduct
including site interactions, oversight of CRO physician and safety activities, and special safety
monitoring and evaluations (infusion reactions, renal function, etc.)
 Participated in the EOP2 FDA meeting, prepared SPA submission, conducted medical Phase 3
studies, analyzed and interpreted data, wrote CSRs and BLA submission (executive summaries and
all medical safety assessments in ISS, edited entire document).
 Served on Savient team for the FDA advisory committee.
 Responsible for KOL relationships and development.
 Represented Savient in OMERACT with experience in gout, psoriatic arthritis, RA, fibromyalgia.
 Medical support for commercialization.
 Responsible for publications - Established an investigator publication committee with multiple
abstract and publication submissions/acceptances.
BRISTOL-MYERS SQUIBB COMPANY, Plainsboro, NJ 5/2003-1/2005
Manufactures prescription pharmaceuticalsin several therapeutic areasincluding cancer, HIV/AIDS,
cardiovascular disease,diabetes and psychiatric disorders.
Director, Medical Strategy/Affairs (Abilify Launch Team)
 Initiated and developed strategic direction, and directed the Abilify investigator initiated trial program
(>120 trials) with matrix management of legal and the MSL manager.
 Provided general medical affairs support including marketing team support, product support, medical
legal copy review, medical education activities, publication committee, and training of sales, MSLs,
and speakers.
NOVARTIS PHARMACEUTICALS CORP., East Hanover, NJ 8/1999-5/2003
Multi-national pharmaceutical company that manufactures pharmaceuticals,vaccines, diagnostics and
consumer products.
Director, Clinical Development and Medical Affairs
 Provided medical support for projects in Phases 1 – 4, including early development compounds for
bipolar, iloperidone, Trileptal, and rufinamide.
 Psychiatric safety analysis for Trileptal approvable letter.
 First-in-man study of depot iloperidone (PK driven dose ranging) – Project physician monitoring and
safety.
 Internal expert consultant in Bipolar disorder
 Empaneled and led scientific advisory board to support company’s entry into bipolar
development.
 Extensive collaboration with Commercial Development
 Led safety group of physicians in preparation to write iloperidone ISS (harmonization of clinical and
safety databases and SAE narratives).
 Led a special project to bring laymen patients into development teams and developed a proposal to
have an international leadership site for this and for patient outcomes development at the Mario Negri
Institute.

4. P a g e | 4
 Developed a soluble biomarker translational medicine program in neuroscience that included new
intramural basic science and clinical project collaboration.
UNIVERSITYMISSISSIPPI MEDICAL CENTER, Jackson MS 4/1998-8/1999
Associate Professor ofPsychiatry/Director ofStudent Education
 Psychotherapy and case management supervision. Conduct of case conferences.
 Attending: Medical Psychiatry Inpatient Unit, Psychiatry Outpatient Clinic, Consultation/Liaison
Service
 Consulting Psychiatrist: Rankin County and Parchman Prisons
 Sub-investigator for Eli Lilly Alzheimer’s disease study
 Curriculum Committee, University of Mississippi Medical Center
 Clinical Sciences Promotions Committee
 Basic Sciences Promotions Committee
 Ethics Committee and Ethics Consultation Group
 Chairman, Oversight Committee of The University Psychiatric Associates (Practice Plan)
 Ad Hoc reviewer for NIMH Intramural research
MARYLAND PSYCHIATRIC RESEARCH CENTER, Catonsville MD 7/1985-4/1998
Schizophrenia research institute of the University of Maryland at Baltimore School of Medicine
Assistant Professor ofPsychiatry, Outpatient Research Division 1989-1998
 Research Fellow 1985-1987
 Advanced Research Fellow 1987-1989
 Visiting Scientist, Retrovirus Biology Laboratories, Department of Comparative Medicine, The Johns
Hopkins University School of Medicine, Baltimore, Maryland 1989-1991
 Visiting Scientist, Viral Immunopathogenesis Laboratory, Division of Infectious Diseases,
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland
1991-1997
 Guest Worker, Neuroimmunopathogenesis Section, Laboratory of Pediatric Viral Diseases and
Respiratory viruses, division of Viral Products,Center for Biologics Evaluation and Research,FDA,
Bethesda,MD. 1996-1998
 Psychiatry Associate,GreenSpring of Maryland, 5565 Sterrett Place,Columbia, Maryland 21044
1995-1998
 Visiting Scientist, Department of Psychiatry, The Johns Hopkins University School of Medicine,
Baltimore, Maryland 1997-1998
 Guest Worker, Neuroimmunopathogenesis Section, Laboratory of Pediatric Viral Diseases and
Respiratory viruses, division of Viral Products,Center for Biologics Evaluation and Research,FDA,
Bethesda,MD. 1996-1998
 Institutional Animal Care and Use Committee, University of Maryland, School of Medicine. 1991-
1998
 Psychotherapy supervisor, Maryland Psychiatric Research Center Outpatient Research Program 1991-
1998
EDUCATION
Faculty Level Training in Virology, Retrovirus Biology Laboratory, Johns Hopkins University
Advanced Research Fellow, Maryland Psychiatric Research Center, Baltimore, MD
Research Fellow, Maryland Psychiatric Research Center, Baltimore, MD
Chief Resident/Instructor, Yale Psychiatric Institute, New Haven, CT
Residency in Psychiatry, Yale University School of Medicine, New Haven, CT.
M.D., University of Texas Medical Branch, Galveston, Texas.
B.S., BioMedical Science (Chemistry/Biology double major, Mathematics minor) – West Texas State
University – Summa Cum Laude
A.S., Highest Honors, South Plains College, Levelland, Texas
BOARD CERTIFICATION:

5. P a g e | 5
1987 American Board of Psychiatry and Neurology, Certificate # 29732
LICENSURE:
Maryland Medical License Number D32523
Texas Medical License Number F-7284
Mississippi State License Number 15823
PATENTS:
Methods for Lowering Elevated Uric Acid Levels Using Intravenous Injection of PEG-
Uricase. #11/899,688.
Developments Related to the Treatment of Gout. #61/269,669.
Alpha 1-Protease Inhibitor for Delaying the Onset or Progression of Pulmonary Exacerbations
(#61/581,708)
Alpha 1-Protease Inhibitor for Delaying the Onset or Progression of Pulmonary Exacerbations
(EU#12808897.8/2758065)
HONORS:
Phi Theta Kappa, 1974.
Outstanding Academic Award in Chemistry, South Plains College, 1974.
A.S. Degree with highest honors, South Plains College, 1974.
Robert A. Welch Foundation Scholarship, 1975-76.
Beta Beta Beta Biological Honor Society Historian,1976.
Ex-students Association Scholarship, 1975-76.
Alpha Chi, 1976.
Who's Who in American Colleges and Universities, 1976.
Plettner Award, 1975-76.
B.S. Degree,Summa Cum Laude, 1976.
Stanley Foundation Research Award,Scholars Program, 1989-90.
Maryland Psychiatric Research Center, Clinical Research Center
Young Investigator, 1989-90.
Distinguished Alumnus Award,South Plains College, 1990.
Who’s Who in Medicine and Health Care 1999-2002.
Who’s Who in America 2001
Bristol-Myers Squibb U.S. Medical Affairs Teamwork Award 2004
Savient Spot Award – January 30, 2009
PROFESSIONAL MEMBERSHIP:
1988 - Present American Psychiatric Association
Association for the Advancement of Science
1988 – 1999 American Society of Virology
Society for Neuroscience
EDITORIAL TASKS:
Reviewer for:
Journal of Nervous and Mental Disease Schizophrenia Bulletin
American Journal of Psychiatry, Book Forum Archives of General Psychiatry
Neuroscience and Biobehavioral Reviews, Psychiatry Research
Biological Psychiatry

6. P a g e | 6
Honorable Editor – Journal of Human Virology and Retrovirology
GRANT SUPPORT:
Principal Investigator:
NARSAD Independent Investigator Award, "Borna Disease Virus Detection and Serology in
Schizophrenia," 9/15/95-9/14/97, $100,000, Principal Investigator.
Theodore & Vada Stanley Foundation Research Award,"Borna Disease Virus and the CNS in
Severe Mental Illness," 8/01/95-7/31/97, $120,000.
5 K20 MH00814 Scientist Development Award for Clinicians, "Neuroimmunology/virology of
Schizophrenia," 1990-1995, $397,212.
NARSAD Young Investigator Award 1989-1991, $60,000.
MH09595-01 National Research Service Award,"Attributional Style and Depression in
Schizophrenia," 1987-1989, $66,800, Principal Investigator.
NARSAD Award 1987-1988, $25,000, Principal Investigator.
Investigator/Participant:
P50 MH40279 CRC: Classification and Course of the Schizophrenias, Principal Investigator:
William T. Carpenter,Jr., M.D.,7/1/90-6/30/95, $385,474 (1990-1991), Investigator.
MH44211-01 Neuroscience Center for Research in Schizophrenia. Principal Investigator: William
T. Carpenter,Jr., M.D.,7/1/88-6/30/93, $611,522 (1990-1991), Coordinator for
Neuroimmunovirology module.
Eli Lilly: Comparison of Olanzepine vs Risperidone in the Treatment of Negative Symptoms in the
Elderly Adult with Schizophrenia. 9/22/98-August 1999. Investigator
PUBLICATIONS:
Chapters:
Waltrip RW, Carrigan DR, Buchanan RW, Carpenter WT. A virus associated immunopathological
theory of schizophrenia. In: Kurstak E, Ed. Psychiatry and Biological Factors,(pp. 23-52) New
York: Plenum, 1991.
Journal articles, refereed:
Seng Yue C, Maroli AN,Lavigne J, Teuscher N, Huang W, Wright D, Horowitz ZD, Waltrip RW,
Benet LZ, Labbé L. Population pharmacokinetic and pharmacodynamic analysis of pegloticase
administered by intravenous infusion in two dose regimens to subjects with chronic gout. In
Preparation.
Sundy JS, Baraf Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J,
White WB,MD, Lipsky PE,MD, Horowitz Z, MD, Huang W, Maroli AN, Waltrip RW, Hamburger
SA, Becker MA. Efficacy and Safety of Pegloticase for the Treatment of Chronic Gout in Subjects
Refractory to Conventional Treatment. Two Randomized Placebo-Controlled Trials. JAMA
306(7):711-720, 2011.

7. P a g e | 7
Schumacher HR, Taylor WJ, Edwards NL, Grainger R, Schlesinger N, Dalbeth N, Sivera F, Singh
JA, Evans R, Waltrip RW, Diaz-Torne C, MacDonald PA,McQueen FM, and Perez-Ruiz F.
Outcome Domains for Studies of Acute and Chronic Gout. OMERACT 9. Journal of
Rheumatology 36(10): 2342-2345, 2009.
Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Naomi Schlesinger, Evans
R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA,McQueen FM, H. Schumacher HR.
Progress in measurement instruments for acute and chronic gout studies. Journal of Rheumatology
36(10): 2346-2355, 2009.
Taylor W, Shewchuk R, Saag K, Schumacher HR, Singh J, Grainger R, Edwards NL, Bardin T,
Waltrip R, Simon L, Burgos-Vargas R. Towards a valid definition of gout flare. Arthritis and
Rheumatism 61(4): 535-43, 2009.
Becker MA,Schumacher HR, Benjamin KL, Gorevic P,Greenwald M, FesselJ, Edwards L,
Kawata AK,Frank L, Waltrip R, Maroli A, Huang B, The Gout NaturalHistory Study Group,
Sundy J. Quality of Life and Disability in Patients with Treatment Failure Gout. Journal of
Rheumatology 36:1041-1048, 2009.
Baraf HSB,Matsumoto AK,Maroli AN,Waltrip RW. Resolution of gouty tophi after twelve weeks
of pegloticase treatment. Arthritis and Rheumatism 58(11): 3632–3634, 2008
Sundy J, Becker MA,Baraf HSB, Barkhuizen A, Moreland L, Huang W, Waltrip RW, Maroli AN,
Horowitz Z. Reduction of plasma urate levels following treatment with multiple doses of
pegloticase (Polyethylene Glycol-Conjugated Uricase) in patients with treatment-failure gout.
Results of a Phase II randomized study. Arthritis and Rheumatism 58(9): 2882-2891, 2008.
Seng Yue C, Huang W, Alton M, Maroli A, Waltrip R, Wright D, Di Marco M. Population
pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and
treatment-failure gout. Journal of Clinical Pharmacology 48(6): 708-718, 2008.
Yamaguchi K, Sawada T, Yamane S, Haga S, Ikeda K, Igata-YiK, Yoshiki K,Matsuoka M, Okabe
H, Horii Y, Nawa Y,Waltrip II RW and Carbone KM. Synthetic peptide-based
electrochemiluminescence immunoassay for anti-Borna disease virus p40 and p24 antibodies in rat
and horse serum. Annals of Clinical Biochemistry 38: 348-355, 2001.
Yamaguchi K, Takashi S, NarakiT, Igata-YiR, Shiraki H, Horii Y, Ishii T, Ikeda K, Asou N,
Okabe H, Mochizuki M, TakahashiK, Yamada S, Waltrip RW, Carbone KM. Detection of Borna
disease virus-reactive antibodies from patients with psychiatric disorders and from horses by
electrochemiluminescence immunoassay. Clinical and Diagnostic Laboratory Immunology
6(5):696-700, 1999.
Katz JB, Alstad D, Jenny AL, Carbone KM, Rubin SA, Waltrip RW. Clinical, serologic and
histopathologic appearance of experimental Borna disease virus in ponies. Journal of Veterinary
Diagnostic Investigation 10:338-343, 1998.
Waltrip RW, Buchanan RW, Carpenter WT,Summerfelt AS, Bryant NL, Kirkpatrick B, Breier A,
Rubin SA, Carbone KM. Borna disease virus antibodies and the deficit syndrome of schizophrenia.
Schizophrenia Research 23:253-257, 1997.
Waltrip RW, Buchanan RW, Summerfelt A, Breier A, Carpenter WT, Bryant NL, Rubin SA,
Carbone KM. Borna disease virus and schizophrenia. Psychiatry Research 56:33-44, 1995.

8. P a g e | 8
Waltrip RW. At Issue: A structured evaluation of Torrey and Yolken's feline viral zoonosis theory
of schizophrenia. Schizophrenia Bulletin 21:173-178, 1995.
Rubin SA, Sierra-Honigmann AM,Lederman HM, Waltrip RW, Eiden JJ, Carbone KM.
Hematological consequences of Borna disease virus infection of rat bone marrow and thymus
stromal cells. Blood 85:2762-2769, 1995.
Breier A, Buchanan RW, Waltrip RW, Listwick S, Holmes C, Goldstein DS. The effect of
clozapine on plasma norepinephrine: Relationship to clinical efficacy. Neuropsychopharmacology,
10(1):1-7, 1994.
Rubin SA, Waltrip RW, Bautista JR, Carbone KM. Borna disease virus in mice: Host-specific
differences in disease expression and viral antigenicity. Journal of Virology, 67(1):548-552, 1993.
Carpenter WT, Kurz R, Kirkpatrick B, Hanlon TE, Summerfelt AT, Buchanan RW, Waltrip RW,
Breier A. Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General
Psychiatry 48:69-72, 1991.
Carbone KM, Park SW, Rubin SA, Waltrip RW, Vogelsang GB. Tolerance to Borna disease:
Association with a maturation defect in the cellular immune response. Journal of Virology
65(11):6154-6164, 1991.
Waltrip RW, Carrigan DR, Carpenter WT. Immunopathology and viral reactivation: A general
theory of schizophrenia. Journal of Nervous and Mental Disease 178(12):729-738, 1990.
Carrigan DR, Waltrip RW. Viral theories in schizophrenia. Current Opinion in Psychiatry 3:14-18,
1990.
Waltrip RW, Strauss ME, Summerfelt AS, Heinrichs DW,Kirkpatrick B, Jauch D, Oltmanns TF.
Rating affective flattening from videotaped interviews. Psychiatry Research 27:199-205, 1989.
Kirkpatrick B, Buchanan RW, Waltrip RW, Jauch D, Carpenter WT. Diazepam treatment of early
symptoms of schizophrenic relapse. Journal of Nervous and Mental Disease 177:52-53, 1989.
Price LH, Nelson CJ, Waltrip RW. Desipramine associated hepatitis. Journal of Clinical
Psychopharmacology 3(4):243-246, August, 1983.
Crowder GA, Waltrip RW. Ideal gas thermodynamic functions of the 2-Halopropenes. Texas
Journal of Science 29(3&4):279-287, December,1977.
Crowder GA, Waltrip RW. Barriers to internal rotation in 2-Bromopropene and 2-Iodopropene.
Texas Journal of Science 28(1&4):219-221, March,1977.
Journal articles, non-refereed:
McGlashan TR, Waltrip RW. Postpsychotic Depression. (Letter). American Journal of Psychiatry
148(4):545, 1991.
Book reviews:
Waltrip RW: Review of Waksman, BH.,ED. Immunologic Mechanisms in Neurologic and
Psychiatric Disease. Research Publications: Association for Research in Nervous and Mental
Disease,Vol. 68, New York, NY: Raven Press,1990. Journal of Nervous and Mental Disease
180(2):140, 1992.

9. P a g e | 9
Waltrip RW: Review of The Psychotherapy of the Self by Muslin HL,and Val ER. New York:
Brunner/Mazel, 1987. American Journal of Psychiatry 148(7):943, 1991.
Waltrip RW: Review of Insanity: The idea and its consequences by Szasz T. New York: John
Wiley & Sons, 1987. American Journal of Psychiatry 145(9):1164-1165, 1988.
Waltrip RW. Review of Family Care of Schizophrenia: A Problem-Solving Approach to the
Treatment of Mental Illness by Falloon IRH, Boyd JH, McGill CW. New York: Guilford Press,
1984. American Journal of Psychiatry 143(4):548, April, 1986.
Abstracts:
Sundy JS, Baraf HSB, Gutierrez-Urena SR, Yood RA, Huang B, Maroli AN, Waltrip R, Horowitz
Z, and Becker MA. Chronic Use of Pegloticase: Safety and Efficacy Update. Arthritis and
Rheumatism 60(10): S417, 2009.
Maroli AN,Waltrip R, Alton M, Baraf HSB,Huang B, Rehrig C, and Ford R. First Application of
Computer-Assisted Analysis of Digital Photographs for Assessing Tophus Response:
Phase 3 Studies of Pegloticase in Treatment Failure Gout. Arthritis and Rheumatism 60(10): S416,
2009.
Baraf HS,Becker MA, Edwards NL,Gutierrez-Urena SR, Sundy JS, Treadwell EL, Vazquez-
Mellado J, Yood RA, Horowitz Z, Huang B, Maroli A,Waltrip R. Tophus Response to Pegloticase
(PGL) Therapy: Pooled Results from GOUT1 and GOUT2, PGL Phase 3 Randomized, Double
Blind, Placebo-controlled Trials. Arthritis and Rheumatism 58(9): S176, 2008.
Edwards NL, Baraf HS,Becker MA,Gutierrez-Urena SR, Sundy JS, Treadwell EL, Vazquez-
Mellado J, Yood RA, Horowitz Z, Huang B, Maroli A,Waltrip R. Improvement in Health-related
Quality of Life (HRQL) and Disability Index in Treatment Failure Gout (TFG) after Pegloticase
(PGL) Therapy: Pooled Results from GOUT1 and GOUT2, Phase 3, Randomized, Double Blind,
Placebo (PBO)-Controlled Trials. Arthritis and Rheumatism 58(9): S178, 2008.
Yood RA, Baraf HS,Becker MA, Edwards NL,Gutierrez-Urena SR, Sundy JS, Treadwell EL,
Vazquez-Mellado J, Horowitz Z, Huang B, Maroli A, Waltrip R. Clinical Homogeneity and
Syndromic Characteristics of Treatment Failure Gout (TFG) in Four Independent Cohorts. Arthritis
and Rheumatism 58(9): S180, 2008.
Sundy JS, Baraf HS, Becker MA,Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vazquez-
Mellado J, Yood RA, Horowitz Z, Huang B, Maroli A,Waltrip R. Efficacy and Safety of
Intravenous (IV) Pegloticase (PGL) in Subjects with Treatment Failure Gout (TFG): Phase 3 Results
from GOUT1 and GOUT2. Arthritis and Rheumatism 58(9): S400, 2008.
Edwards NL, Blume S, Pan F, Becker MA, Schumacher HR,Waltrip R, Forsythe A. Work
Productivity Loss Due to Flares and Treatment Failure Gout (TFG). Arthritis and Rheumatism
58(9): S673, 2008.
Becker MA,Treadwell EL, Baraf HS,Edwards NL, Gutierrez-Urena SR, Sundy JS, Vazquez-
Mellado J, Yood RA, Horowitz Z, Huang B, Maroli A,Waltrip R, Wright D. Immunoreactivity and
Clinical Response to Pegloticase (PGL): Pooled Data from GOUT1 and GOUT2, PGL Phase 3
Randomized, Double Blind, Placebo-controlled Trials. Arthritis and Rheumatism 58(9): S880,
2008.

10. P a g e | 10
Waltrip RW, Rosario-Jansen T, Seng-Yue CB, Marier J, Huang B, Alton M, Maroli AN, Wright
DE, Di Marco M. Pharmacokinetics and Pharmacodynamics of PEG-Uricase in Patients with
Hyperuricemia and Treatment Failure Gout. Ann Rheum Dis 66(Suppl II):236, 2007.
Kawata AK,Benjamin KL, Waltrip RW, Huang B, Maroli AN,Sundy JS, Becker MA,Schumacher
HR, Edwards NL, Frank L. Validation of the SF-36 and HAQ-DI in Patients with Treatment Failure
Gout. Ann Rheum Dis 66(Suppl II):236-7, 2007.
Waltrip RW, Alton M, Huang B, Maroli AN. Weekly Flare Burden Index: A New Metric for
Evaluating Gout Treatment. Ann Rheum Dis 66(Suppl II):624, 2007.
Sundy JS, Schumacher HR,Becker MA,Edwards NL,Hatoum H, Pickard AS, Waltrip RW.
Quality of life in patients with treatment-failure gout. Annals Rheum Dis 65(Suppl II):271, 2005.
Waltrip RW, Buchanan RW, Summerfelt A, Breier A, Carpenter WT, Rubin SA, Carbone KM.
Schizophrenia, Borna disease, and neurological abnormalities in a monozygotic twin study cohort.
Biological Psychiatry 30:544 (152), 1996.
Waltrip RW, Torrey EF, King LR, Weinberger DR,Rickler KC, Rubin SA, Carbone KM.
Schizophrenia and Borna disease - clinical relationships in a monozygotic twin study cohort.
Journal of Neurovirology 2(3):220, 1996.
Waltrip RW, Buchanan RW, Summerfelt A, Breier A, Carpenter WT, Bryant NL, Kirkpatrick B,
Rubin SA, Carbone KM. Borna disease virus antibodies and schizophrenia. Schizophrenia
Research 15(1,2):136, 1995.
Breier A, Buchanan RW, Kirkpatrick B, Waltrip II RW, Davis OR, Moricle LA, Bryant N,
Carpenter,Jr. WT. Clozapine in schizophrenic outpatients: Efficacy, long term outcome, and
relationship to prefrontal cortex. Schizophrenia Research,9(2,3):257-258, 1993.
Waltrip RW, Buchanan RW, Carbone KM, Breier A, Narayan O, Carpenter WT. Abstract:Borna
disease virus and schizophrenia: Preliminary results. Schizophrenia Research 4(3):374, 1991.
Abstracts and Presentations Accepted for National and International Meetings
Lee B, Tumu P,Waltrip R, PaulI. Effects of LP-BM5 infection on reaction time and errors in a
sustained attention task in C57BL/6 mice. 29th Annual Meeting of the Society for Neuroscience,
October 23-28, 1999, Miami Beach,Fl.
Waltrip RW, Lieberman J, Robinson D, Bilder RM, Alvir JM, King LR, Summerfelt A, Rubin SA,
Carbone KM. First episode schizophrenia and Borna disease virus. International Congress on
Schizophrenia Research,Colorado Springs, CO, April 1997.
Waltrip RW, Lieberman JA,Robinson DG, Bilder RM, Alvir JM, King LR, Summerfelt A, Rubin
SA, Carbone KM. Borna disease virus seroconversion in first episode schizophrenia. Biological
Psychiatry Annual Meeting, May 1997.
Waltrip RW, Lieberman JA,Robinson DG, Bilder RM, Alvir JM, King LR, Summerfelt A, Rubin
SA, Carbone KM. Borna disease virus antibodies in first episode schizophrenia. 16th Annual
Meeting of the American Society for Virology, July 1997.
R.W.Waltrip, J.A.Lieberman, D.G.Robinson, R.M. Bilder, J.M. Alvir, L.R.,King, A. Summerfelt,
S.A. Rubin, K.M. Carbone Borna disease virus antibodies in first episode schizophrenia. Presented

11. P a g e | 11
at the 16th annual meeting of the American Society for Virology, July 19-23, 1997 Bozeman,
Montana.
R.W.Waltrip, J.A.Lieberman, D.G.Robinson, R.M. Bilder, J.M. Alvir, L.R. King, A. Summerfelt,
S.A. Rubin, K.M. Carbone. Borna disease virus and first episode schizophrenia. Presented at the
27th annual meeting of the Society for Neuroscience October 25-30, 1997, New Orleans,Louisiana.
Carbone KM, Rubin SA, Waltrip RW. The quagmire of BDV diagnostic tests. Presented at the 3rd
Symposium on the Neurovirology and Neuroimmunology of Schizophrenia and Bipolar Disorder.
October 23-25, 1997 Bethesda,Maryland.
Rubin SA, Waltrip RW, Carbone KM. Congenital cerebellar developmental damage associated
with perinatal neurovirulent viral infection. FDA forum on Regulatory Sciences, Washington
Convention Center, Washington, D.C.,1996.
Waltrip RW, Torrey EF, King LR, Weinberger DR,Rickler KC, Rubin SA, Carbone KM.
Schizophrenia and Borna disease - clinical relationships in a monozygotic twin study cohort. 15th
Annual Meeting of the American Society of Virology, Ontario, Canada, 1996.
Waltrip RW, Lieberman J, Robinson D, Bilder RM, Alvir JM, King LR, Rubin SA, Carbone KM.
Borna disease virus serology in a first episode schizophrenia cohort. 2nd Symposium on the
Neurovirology and Immunology of Schizophrenia and Bipolar Disorder, Baltimore MD, November
1996.
Waltrip RW, Torrey EF, King LR, Weinberger DR,Rickler KC, Rubin SA, Carbone KM. Borna
disease virus antibodies in a schizophrenia - monozygotic twin study cohort. To be presented at the
14th Annual Meeting of the American Society of Virology, Austin, Texas,July 8-12, 1995.
Waltrip RW, Torrey EF, King LR, Weinberger DR,Rickler KC, Rubin SA, Carbone KM. Borna
disease virus correlates in a schizophrenia monozygotic twin study cohort. Society for
Neuroscience Annual Meeting, San Diego CA, November 11-16, 1995.
Waltrip RW, Torrey EF, King LR, Weinberger DR,Rickler KC, Rubin SA, Carbone KM. Borna
disease virus antibodies in a schizophrenia-monozygotic twin study cohort. Presented at the Johns
Hopkins University Department of Medicine Research Retreat,October 7,1995.
Waltrip RW, Buchanan RW, Summerfelt A, Breier A, Carpenter WT, Bryant NL, Kirkpatrick B,
Rubin SA, and Carbone KM. Borna disease virus antibodies and schizophrenia. Johns Hopkins
University Department of Medicine Research Retreat,October 7,1994.
Waltrip RW, Buchanan RW, Breier A, Rubin SA, Carbone, KM. Human antibodies to Borna
Disease Virus: Clinical Significance. Presented at the 21st Annual Mid-Atlantic Immunobiology
Conference,Cape May, New Jersey,May 7-9, 1993.
Rubin SA, Sierra-Honigmann AM,Waltrip RW, Carbone KM. Detection of Borna Disease Virus in
Cultured Bone Marrow and Thymus Cells from Lewis Rats. Presented at the 21st Annual Mid-
Atlantic Immunobiology Conference,Cape May, New Jersey,May 7-9, 1993.
Waltrip RW, Rubin SA, Summerfelt A, Buchanan RW, Breier A, Carpenter WT,and Carbone KM.
Borna Disease Virus antibody analysis in sera from schizophrenic patients. Presented at the 12th
Annual Meeting of the American Society for Virology, Davis, California, July 10-14, 1993.

12. P a g e | 12
Waltrip RW, Rubin SA, Summerfelt A, Buchanan RW, Breier A, Carpenter WT,and Carbone KM.
Borna Disease Virus antibodies in sera from schizophrenic patients: Clinical correlations. Presented
at the IXth International Congress of Virology, Glasgow, August 8-13, 1993.
Breier A, Buchanan RW, Waltrip RW, Bryant NL, Goldstein DS. Clozapine's superior efficacy is
related to its noradrenergic properties. Presented at the 1993 Annual Meeting of the Society for
Neuroscience,Washington, D.C.,November 7-12, 1993.
Waltrip RW, Buchanan RW, Summerfelt A, Breier A, Carpenter WT, Rubin SA, Carbone KM.
Schizophrenia and Borna Disease Virus Antibodies. Presented at the 1993 Annual Meeting of the
Society for Neuroscience, Washington, D.C.,November 7-12, 1993.
Waltrip RW, Buchanan RW, Summerfelt A, Breier A, Carpenter WT, Rubin SA, Carbone KM.
Borna disease virus antibody analysis and schizophrenia: Clinical correlates. Presented at the Johns
Hopkins University Department of Medicine Research Retreat. October,1993.
Rubin SA, Waltrip RW, Bautista J, and Carbone KM. Borna disease in mice. Presented at the
Johns Hopkins University Department of Medicine Research Retreat. October,1992.
Waltrip RW, Buchanan RW, Carpenter WT,Breier A, Carbone KM. Borna disease virus antibodies
in schizophrenic patients: Preliminary findings. Presented at the 10th annual meeting of the
American Society for Virology, Colorado State University, Fort Collins, Colorado, July 7-11, 1991.
Carbone KM, Park SW, Waltrip RW. Tolerance to Borna Disease in the neonatally infected rat is
due to processing of immune cells after release from the bone marrow. Presented at the 10th annual
meeting of the American Society for Virology, Colorado State University, Fort Collins, Colorado,
July 7-11, 1991.
Carbone KM, Park Suk, Rubin SA, Rhodes D, Waltrip RW. The immunopathogenesis of Borna
Disease. Presented at the Eighth International Conference on Negative Strand Viruses, Charleston,
South Carolina, September 15-20, 1991.
Carbone KM, Rubin SA, Park SW, Sierra-Honigmann AM, Waltrip RW, Lipkin WI, and Yolken
RH. Neurotropism of Borna disease virus is linked to the production of nerve growth factor and
other soluble factors by neural cells. Presented at the 1991 Annual Meeting of the Society of
Neuroscience,New Orleans, Louisiana, November 10-15, 1991.
Sierra-Honigmann AM, Lipkin WI, Griffin JW, Waltrip RW,Yolken RH, Carbone KM. PCR
Amplification of Borna Disease Virus (BDV) specific sequences in non neural tissues and body
fluids in newborn, chronic, and acutely-infected rats. Presented at the 1991 Annual Meeting of the
Society of Neuroscience,New Orleans,Louisiana, November 10-15, 1991.
MAJOR INVITEDSPEECHES, GRAND ROUNDS:
Waltrip RW. The Profile of Early Depression. Presentation at Grand Rounds, Department of
Psychiatry, University of Mississippi Medical Center, Jackson,MS, October 8, 1998.
Waltrip RW. The Profile of Early Depression (and the surprising association with blood pressure,
cardiac status, cancer probability and survival in depressed patients) Presentation at the Symposium:
Psychiatric Issues in Medical Practice,Crown Plaza Hotel, Jackson, MS, August 15, 1998.
Waltrip RW. Research Seminar, Department of Psychiatry, University of Mississippi Medical
Center,Jackson, MS, December,1997.

13. P a g e | 13
Waltrip RW. Borna disease virus and mental disease. Presentation at Brookhaven National
Laboratory. New York. December 11, 1997.
Waltrip RW Borna disease and schizophrenia. Invited presentation at the Clifford W. Beers
National Mental Health Conference,Alexandria, Virginia, May 19-22, 1993.
Waltrip RW. Research Seminar, Department of Psychiatry, University of Texas Medical Branch,
Galveston, TX, May, 1992.
Waltrip RW. Research Seminar, NIMH Mentored Awardees Meeting, Rockville, MD, May, 1992.